| Home | E-Submission | Sitemap | Contact Us |  
The Korean Journal of Pathology 2002;36(6): 382-388.
Altered Expression of p53, p21WAF1, p16, Rb, Smad4 and c-erbB-2 in Resected Pancreatic Ductal Adenocarcinoma.
Yun Kyung Kang, Woo Ho Kim
1Department of Pathology, Inje University Seoul Paik Hospital, Seoul, Korea. jadepaka@hanmail.net
2Departmant of Pathology Seoul National University College of Medicine, Seoul, Korea.
BACKGROUND: Our aim was to undertake a comprehensive analysis of the expression of key molecular markers in a series of pancreatic ductal adenocarcinomas and to determine their association with clinicopathologic variables. METHODS: By using immunohistochemical staining, we examined the expressions of five tumor suppressor genes (p53, p21WAF1, p16, Rb, Smad4) and a growth factor receptor (c-erbB-2) in 52 surgically resected pancreatic ductal adenocarcinomas. RESULTS: Abnormal nuclear overexpression of p53 was noted in 28/52 (53.8%) cases. Total loss of p21WAF1, p16, Rb, and Smad4 was detected in 15/52 (28.8%), 33/52 (63.5%), 4/52 (7.7%), and 26/52 (50%) cases, respectively. Overexpression of c-erbB-2 was noted in 21/52 (40.4%) cases. Forty-nine (94.2%) cases revealed aberration of at least one of the markers examined. There was a positive correlation between p53 and c-erbB-2 overexpression (p<0.05). Among the examined genes, overexpression of c-erbB-2 was found to have a positive relationship with the tumor stage (p<0.05). There was also a significant correlation between the histologic grade and the number of abnormally expressed genes per tumor (p<0.05). CONCLUSION: Among the various tumor-associated proteins evaluated in this study, c-erbB-2 could have the most likely clinical implication.
Key Words: Carcinoma; Pancreatic Ductal; Genes; Tumor suppressor; Receptor; erbB-2; Immunohistochemistry